Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
J Prev Alzheimers Dis ; 11(3): 589-600, 2024.
Article in English | MEDLINE | ID: mdl-38706275

ABSTRACT

BACKGROUND: Alzheimer's disease (AD), the most common type of irreversible dementia, is predicted to affect 152 million people by 2050. Evidence from large-scale preventive randomized controlled trials (RCTs) on modifiable risk variables in Europe has shown that multi-domain lifestyle treatments for older persons at high risk of dementia may be practical and effective. Given the substantial differences between the Chinese and European populations in terms of demographics and living conditions, direct adoption of the European program in China remains unfeasible. Although a RCT has been conducted in China previously, its participants were mainly from rural areas in northern China and, thus, are not representative of the entire nation.There is an urgent need to establish cohorts that represent different economic, cultural, and geographical situations in order to explore implementation strategies and evaluate the effects of early multi-domain interventions more comprehensively and accurately. MEDTODS: We developed an integrated intervention procedure implemented in urban neighborhood settings, namely China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI). CHINA-IN-MUDI is a 2-year multicenter open-label cluster-randomised controlled trial centered around a Chinese-style multi-domain intervention to prevent cognitive decline. Participants aged 60-80 years were recruited from a nationally representative study, i.e. China Healthy Aging and Dementia Study cohort. An external harmonization process was carried out to preserve the original FINGER design. Subsequently, we standardized a series of Chinese-style intervention programs to align with cultural and socioeconomic status. Additionally, we expanded the secondary outcome list to include genomic and proteomic analyses. To enhance adherence and facilitate implementation, we leveraged an e-health application. RESULTS: Screening commenced in July 2022. Currently, 1,965 participants have been randomized into lifestyle intervention (n = 772) and control groups (n = 1,193). Both the intervention and control groups exhibited similar baseline characteristics. Several lifestyle and vascular risk factors were present, indicating a potential window of opportunity for intervention. The intervention will be completed by 2025. CONCLUSIONS: This project will contribute to the evaluation of the effectiveness and safety of intervention strategies in controlling AD risk and reducing clinical events, providing a basis for public health decision-making in China.


Subject(s)
Cognitive Dysfunction , Aged , Female , Humans , Male , Middle Aged , Alzheimer Disease/prevention & control , China/epidemiology , Cognitive Dysfunction/prevention & control , Life Style
2.
Rinsho Byori ; 45(11): 1098-102, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9396352

ABSTRACT

We examined the differences in molar absorptivity of 4-NP obtained using different kits for ALP measurement and different instruments. The apparent molar absorptivity of 4-NP in the same reaction solution determined by six different instruments was 15.98, 16.72, 16.06, 17.00, 16.27, 17.62 and that using four different reaction solution kits for ALP with the same instrument was 16.90, 17.38, 17.72, 16.11. We measured ALP in three serum samples with six instruments using the same kit and in twelve serum samples with the same instrument using four kits. ALP activities measured using the same molar absorptivity value differed with the instrument(p < 0.01). However, those measured using the apparent molar absorptivity value for each instrument revealed no significant differences(p > 0.05). In conclusion, we suggest that standard material should be contained in each kit for enzyme measurement and the apparent epsilon for each kit and instrument should be obtained to minimize the systematic error caused by using the same epsilon in different laboratories.


Subject(s)
Alkaline Phosphatase/blood , Clinical Enzyme Tests/instrumentation , Nitrophenols/chemistry , Clinical Enzyme Tests/methods , Humans , Molecular Structure , Reagent Kits, Diagnostic/standards , Solutions
3.
Zhongguo Zhong Yao Za Zhi ; 18(6): 367-8, 383, 1993 Jun.
Article in Chinese | MEDLINE | ID: mdl-8274218

ABSTRACT

Blood-lipid decreasing action of total saponins of Panax notoginseng was studied. The results showed that after the saponins were given po 100 mg/kg and 200 mg/kg to rats and quails, two high lipid model animals, for seven days, their TCH and TG were evidently decreased (P < 0.05).


Subject(s)
Cholesterol/blood , Drugs, Chinese Herbal , Hypolipidemic Agents/pharmacology , Saponins/pharmacology , Triglycerides/blood , Animals , Drugs, Chinese Herbal/chemistry , Female , Ginsenosides , Male , Quail , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...